TIMP1 and melanoma: Figure 4B also confirms that PDK1 is a downstream target of PI3K in this model. The efficiency of the PI3K inhibitor, LY294002, in abrogating AKT activation is shown in Figure 4C. These data show that Timp1 confers cell survival by activating PDK1 along melanoma progression and that in metastatic cells AKT activation also contributes to anoikis resistance (Figure 4G).